Related Experiment Video
Updated: Jul 2, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer
Dmitri Lodygin1, Valery Tarasov, Alexey Epanchintsev
1Molecular Oncology, Max-Planck-Institute of Biochemistry, Martinsried, Germany.
Abstract:
Recently, we and others identified the microRNA miR-34a as a target of the tumor suppressor gene product p53. Ectopic miR-34a induces a G(1) cell cycle arrest, senescence and apoptosis. Here we report that miR-34a expression is silenced in several types of cancer due to aberrant CpG methylation of its promoter. 19 out of 24 (79.1%) primary prostate carcinomas displayed CpG methylation of the miR-34a promoter and concomitant loss of miR-34a expression. CpG methylation of the miR-34a promoter was also detected in breast (6/24; 25%), lung (7/24; 29.1%), colon (3/23; 13%), kidney (3/14; 21.4%), bladder (2/6; 33.3%) and pancreatic (3/19; 15.7%) carcinoma cell lines, as well as in melanoma cell lines (19/44; 43.2%) and primary melanoma (20/32 samples; 62.5%). Silencing of miR-34a was dominant over its transactivation by p53 after DNA damage. Re-expression of miR-34a in prostate and pancreas carcinoma cell lines induced senescence and cell cycle arrest at least in part by targeting CDK6. These results show that miR-34a represents a tumor suppressor gene which is inactivated by CpG methylation and subsequent transcriptional silencing in a broad range of tumors.
Insights
MicroRNA miR-34a, a tumor suppressor, is silenced in many cancers by promoter CpG methylation. Reactivating miR-34a induces cell cycle arrest and senescence, highlighting its role in cancer development.
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Background:
- The microRNA miR-34a is a known target of the tumor suppressor gene p53.
- miR-34a can induce cell cycle arrest, senescence, and apoptosis when ectopically expressed.
Purpose of the Study:
- To investigate the role of miR-34a in various cancers.
- To determine if aberrant CpG methylation silences miR-34a expression in tumors.
Main Methods:
- Analysis of miR-34a promoter methylation in primary tumors and cell lines using CpG methylation assays.
- Quantification of miR-34a expression levels.
- Assessment of cell cycle arrest, senescence, and apoptosis upon miR-34a re-expression.
- Identification of miR-34a targets, such as CDK6.
Main Results:
- miR-34a expression is frequently silenced in prostate cancer (79.1%) due to CpG methylation of its promoter.
- CpG methylation and silencing of miR-34a were also observed in breast, lung, colon, kidney, bladder, pancreatic, and melanoma cancers.
- Silencing of miR-34a was found to be dominant over p53-mediated transactivation.
- Re-expression of miR-34a in cancer cell lines induced senescence and cell cycle arrest, partly via targeting CDK6.
Conclusions:
- miR-34a functions as a tumor suppressor gene.
- Inactivation of miR-34a through CpG methylation and transcriptional silencing is a common event in a wide spectrum of human cancers.
Related Concept Videos
MicroRNAs
MicroRNAs
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
Abnormal Proliferation
Induced Pluripotent Stem Cells
Somatic cells are...
